Ipercortisolismo funzionale e sue possibili conseguenze cliniche

Springer Science and Business Media LLC - Tập 22 - Trang 231-237 - 2021
Marianna Martino1, Giorgio Arnaldi1
1Clinica di Endocrinologia e Malattie del Metabolismo, A.O.U. Ospedali Riuniti di Ancona, Università Politecnica delle Marche, Ancona, Italia

Tóm tắt

L’ipercortisolismo funzionale rappresenta una condizione di attivazione cronica dell’asse ipotalamo-ipofisi-surrene che si verifica in condizioni cliniche eterogenee (depressione e altri disordini psichici, disturbi del comportamento alimentare, diabete mellito, obesità, alcolismo, sindrome dell’ovaio policistico, sindrome delle apnee ostruttive notturne, lavoro a turni). Solitamente è un ipercortisolismo di lieve entità e reversibile alla remissione della condizione sottostante. Deve essere distinto dalla Sindrome di Cushing con la quale, però, condivide manifestazioni cliniche, alterazioni biochimiche e problematiche di diagnostica differenziale. Si può ipotizzare che l’ipercortisolismo funzionale abbia comunque un’azione deleteria tessuto-specifica. In questa rassegna verranno illustrati sinteticamente meccanismi ed effetti nocivi dell’ipercortisolismo funzionale.

Tài liệu tham khảo

Tirabassi G, Boscaro M, Arnaldi G (2014) Harmful effects of functional hypercortisolism: a working hypothesis. Endocrine 46(3):370–386 Scaroni C, Albiger NM, Palmieri S et al. (2020) Approach to patients with pseudo-Cushing’s states. Endocr Connect 9(1):R1–R13 Arnaldi G, Mancini T, Tirabassi G et al. (2012) Advances in the epidemiology, pathogenesis, and management of Cushing’s syndrome complications. J Endocrinol Invest 35:434–448 Thakore JH, Richards PJ, Reznek RH et al. (1997) Increased intra-abdominal fat deposition in patients with major depressive illness as measured by computed tomography. Biol Psychiatry 41:1140–1142 Broadley AJ, Korszun A, Abdelaal E et al. (2006) Metyrapone improves endothelial dysfunction in patients with treated depression. J Am Coll Cardiol 48:170–175 Thomson F, Craighead M (2008) Inovative approaches for the treatment of depression: targeting the HPA axis. Neurochem Res 33:691–707 Michelson D, Stratakis C, Hill L et al. (1996) Bone mineral density in women with depression. N Engl J Med 335:1176–1181 Steiger A, von Bardeleben U, Wiedemann K et al. (1991) Sleep EEG and nocturnal secretion of testosterone and cortisol in patients with major endogenous depression during acute phase and after remission. J Psychiatr Res 25:169–177 Nasser FJ, Merula de Almeida M, Saraiva da Silva L et al. (2016) Psychiatric disorders and cardiovascular system: heart-brain interaction. Int J Cardiovasc Sci 29(1):65–75 Castro–Fornieles J, Bargalló N, Lázaro L et al. (2009) A cross-sectional and follow-up voxel-based morphometric MRI study in adolescent anorexia nervosa. J Psychiatr Res 43:331–340 Misra M, Prabhakaran R, Miller KK et al. (2008) Prognostic indicators of changes in bone density measures in adolescent girls with anorexia nervosa-II. J Clin Endocrinol Metab 93:1292–1297 Naessén S, Carlström K, Glant R et al. (2006) Bone mineral density in bulimic women–influence of endocrine factors and previous anorexia. Eur J Endocrinol 155:245–251 Abdelhadi Z, Bladbjerg EM, Møller Jensen D et al. (2020) Venous thromboembolism in anorexia nervosa: four cases from a specialized unit. Indication for thromboprophylaxis? Eat Weight Disord 25(6):1833–1837 Donoghue K, Rose A, Coulton S et al. (2020) Double-blind, placebo-controlled trial of mifepristone on cognition and depression in alcohol dependence. Trials 21(1):796 Van der Valk ES, Savas M, van Rossum EF (2018) Stress and obesity: are there more susceptible individuals? Curr Obes Rep 7(2):193–203 Stalder T, Steudte–Schmiedgen S, Alexander N et al. (2017) Stress-related and basic determinants of hair cortisol in humans: a meta-analysis. Psychoneuroendocrinology 77:261–274 Noppe G, Van Den Akker ELT, De Rijke YB et al. (2016) Long-term glucocorticoid concentrations as a risk factor for childhood obesity and adverse body-fat distribution. Int J Obes 40(10):1503–1509 Min L (2016) Functional hypercortisolism, visceral obesity, and metabolic syndrome. Endocr Pract 22(4):506–508 Gant CM, Minovic I, Binnenmars H et al. (2018) Lower renal function is associated with derangement of 11-beta hydroxysteroid dehydrogenase in type 2 diabetes. J Endocr Soc 2(7):609–620 Oltmanns KM, Dodt B, Schultes B et al. (2006) Cortisol correlates with metabolic disturbances in a population study of type 2 diabetic patients. Eur J Endocrinol 154:325–331 Andrews RC, Rooyackers O, Walker BR (2003) Effects of the 11 beta-hydroxysteroid dehydrogenase inhibitor carbenoxolone on insulin sensitivity in men with type 2 diabetes. J Clin Endocrinol Metab 88:285–291 Gregory S, Hill D, Grey B et al. (2020) 11\(\beta \)-hydroxysteroid dehydrogenase type 1 inhibitor use in human disease – a systematic review and narrative synthesis. Metabolism 108:154246 Reynolds RM, Strachan MW, Labad J et al. (2010) Morning cortisol levels and cognitive abilities in people with type 2 diabetes: the Edinburgh type 2 diabetes study. Diabetes Care 33:714–720 Sandeep TC, Yau JL, MacLullich AM et al. (2004) 11Beta-hydroxysteroid dehydrogenase inhibition improves cognitive function in healthy elderly men and type 2 diabetics. Proc Natl Acad Sci USA 101:6734–6739 Zarković MJ, Penezić Z, Trbojević B et al. (2001) Temporal coupling of luteinizing hormone and follicle stimulating hormone secretion in polycystic ovary syndrome. Gynecol Endocrinol 15:381–388 Bozic J, Galic T, Supe-Domic D et al. (2016) Morning cortisol levels and glucose metabolism parameters in moderate and severe obstructive sleep apnea patients. Endocrine 53(3):730–739 Voinescu BI (2018) Common sleep, psychiatric, and somatic problems according to work schedule: an internet survey in an eastern European country. Int J Behav Med 25(4):456–464